NCT00458016View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MB07803

Daily oral administration

DRUG

Placebo

Daily oral administration

Trial Locations (25)

23249

Richmond

27103

Winston-Salem

28209

Charlotte

28677

Statesville

29407

Charleston

33169

Miami

Miami Gardens

37620

Bristol

43015

Delaware

43302

Marion

44094

Willoughby Hills

45246

Cincinnati

46254

Indianapolis

46260

Indianapolis

59701

Butte

60607

Chicago

60611

Chicago

74104

Tulsa

75231

Dallas

77030

Houston

78229

San Antonio

78404

Corpus Christi

89123

Las Vegas

90057

Los Angeles

94598

Walnut Creek

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY